Revolutionary Biomarker Discovery: Aptamarker allows agnostic screening for biomarkers, transforming disease understanding. Enables patient stratification in clinical trials for enhanced safety and precision medicine. Predictive and Precise Drug Development: Predicts side effects and translates animal model findings for safer drug development. Maps drug binding sites… Read More »Unleashing the Power of Aptamarkers: A New Frontier in Disease Management

In the rapidly advancing field of molecular medicine, researchers are constantly on the lookout for innovative therapies that can target specific disease molecules with precision and efficacy. Aptamers, a class of synthetic oligonucleotides, have emerged as a promising and versatile tool in the quest for… Read More »Aptamers: A Novel Therapeutic Oligonucleotide

Aptamers are engineered molecules that can bind to specific target compounds with high affinity and selectivity, making them valuable tools in various applications. Achieving absolute specificity, or binding to a single compound exclusively, is challenging due to the structural similarities among molecules. However, aptamers can… Read More »The Specificity of Aptamers: Can They Selectively Bind to a Single Compound?

One of the most remarkable aspects of the integration of aptamers with qPCR for protein detection is the unprecedented sensitivity it brings to the table. Traditional protein detection methods, such as ELISA and Western blotting, often struggle to accurately quantify proteins present in very low… Read More »Advancements in Sensitivity: qPCR’s Remarkable Detection of Proteins

We are pleased to announce that our European subsidiary company, NeoNeuro has recently succeeded with a pre-clinical trial of their blood test for brain amyloid with the collaboration of the Centro Hospitalar de Entre o Douro e Vouga, in Santa Maria da Fiera, Portugal. This… Read More »Successful Pre-clinical Trial of Aptamer-based Blood Test for Alzheimer’s Disease